Related Experiment Video
Updated: Jan 16, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
Pharmacokinetics of apixaban in patients with short bowel syndrome: a Bayesian re-estimation approach
Karolína Hronová1, Irena Štenglová Netíková1, Eva Meisnerová2
1Institute of Pharmacology of First Faculty of Medicine, Charles University Prague and General University Hospital in Prague, Prague, Czech Republic.
Background:
Short bowel syndrome (SBS) is a malabsorptive condition that may impair drug absorption, including direct oral anticoagulants such as apixaban. This study aimed to assess whether the pharmacokinetics (PK) of apixaban in patients with SBS differs from those observed in individuals with an intact gastrointestinal (GI) tract, using Bayesian re-estimation with an existing population PK (pop PK) model.
Research Design And Methods:
Thirteen patients with SBS (7 males, 6 females; median age 79 years, weight 76 kg, eGFR 53 mL/min) receiving apixaban (2.5-7.5 mg twice daily) contributed 69 steady-state plasma concentrations. Bayesian re-estimation was performed using a previously published pop PK model in NONMEM v7.4. Model fit was evaluated using goodness-of-fit (GOF) plots and the trends in the distribution of individual ETA-values. Fractional differences in absorption parameters - ka and Frel-between the SBS cohort and the reference population were explored.
Results:
GOF plots showed no significant bias, and the published model predicted apixaban concentrations in the SBS cohort with acceptable accuracy. Estimated absorption parameters in SBS patients were comparable to those in the original population.
Conclusion:
In stabilized SBS patients, the absorption of apixaban may not be significantly altered. Standard dosing of apixaban is expected to be appropriate in this population.
Clinical Trial Registration:
The https://www.isrctn.com/ identifier is ISRCTN80601124.
Related Concept Videos
Dosage Regimens: Partial Pharmacokinetic Parameters
One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution
Measurement of Bioavailability: Pharmacokinetic Methods
Two-Compartment Open Model: IV Bolus Administration
The disparity between drug input and the sum of drug transfer rates between...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
One-Compartment Open Model for IV Bolus Administration: General Considerations
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...

